Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Steven M. Rowe
University of Alabama at Birmingham, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
SYNEDGEN, INC
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The outcome of the research is of significant business interest to the entity and therefore the financial interest could likely change based on the research results
The Mechanism of Tobacco-Induced Decrements in Mucociliary Clearance
PROJECT NARRATIVE While hundreds of millions of people worldwide suffer from chronic obstructive pulmonary disease (COPD) primarily due to cigarette smoking, patients have few treatment options directed at the underlying pathogenesis. The goal of this project is to determine whether specific inhaled chemicals within cigarette smoke, including the reactive aldehyde acrolein, alter the function of the cystic fibrosis transmembrane conductance regulator (CFTR), a key protein we have shown contributes to the pathogenesis of COPD and promotes disease-related mucus obstruction; we will also assess whether scavengers of these chemicals can mitigate these effects. Improving our understanding of the relationship between particular tobacco smoke toxicants and mechanisms underlying COPD, as well as clinical manifestations, will provide insight that can drive the development of novel therapeutic interventions aimed at interrupting or slowing disease progression and improving quality of life for patients with this debilitating lung disease.
Filed on December 02, 2016.
Tell us what you know about Steven M. Rowe's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Steven M. Rowe”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Steven M. Rowe | University of Alabama at Birmingham | Conflict of Interest | SYNEDGEN, INC | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.